In June 2022, Trial Site News published an investigative report revealing a leaked slide presented at a meeting between Pfizer-BioNTech and the EMA. Alexandra (Sasha) Latypova, a former pharmaceutical industry executive who has worked with many companies, including Pfizer, shared the same slide in her Substack on Jan. 10, 2023.
The EMA demanded that Pfizer address these issues: “The truncated forms should be sufficiently characterized, i.e. they should be described, and it should be discussed if the fragmented species are expected to be similar between batches. In addition, the possibility of translated proteins other than the intended spike protein (S1S2), resulting from truncated and/or modified mRNA species should be addressed, and relevant protein characterization data should be provided, if available.”
Pfizer fully recognized the truncated mRNA in its vaccines. Most truncated mRNA is 1,500 to 3,500 nucleotides long with 5’ CAP, missing the Poly(A) tail and the stop codon. They can be translated into a partial spike protein.
Unfortunately, when the mRNA goes to the end of translation, the amino acid chain does not stop prolongation, as no stop signal has been given to them. There are lots of mRNA in the cell. As there is no stop signal, in theory, another mRNA in a cell will take over and continue the unfinished job, prolonging the “spike protein.”
If the same spike mRNA takes over, prolonged spike-like proteins with multiple repeats will form. If different mRNA takes over, unknown types of proteins will be created.
A “Western blot” method is used to identify specific proteins, allowing researchers to verify the size and abundance of a protein of interest.
Because of concerns that incorrect spike protein can cause unexpected injury, the EMA required Pfizer-BioNTech to submit experimental results to demonstrate that truncated COVID-19 vaccine RNA would not produce fragment proteins.